Arresting the inflammatory drive of chronic lymphocytic leukemia with ibrutinib

Pavan Bachireddy; Catherine J. Wu

doi:10.1158/1078-0432.CCR-15-3106

Arresting the inflammatory drive of chronic lymphocytic leukemia with ibrutinib

Pavan Bachireddy, Catherine J. Wu

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

The clinical success of agents targeting the B-cell receptor signaling pathway in chronic lymphocytic leukemia (CLL) may also derive from disrupting the CLL microenvironment. Investigation of the immunomodulatory effects of these agents illuminates the unique immunobiology of CLL and highlights potential targets for dismantling the chronic inflammatory drive.

Original language	English (US)
Pages (from-to)	1547-1549
Number of pages	3
Journal	Clinical Cancer Research
Volume	22
Issue number	7
DOIs	https://doi.org/10.1158/1078-0432.CCR-15-3106
State	Published - Apr 1 2016
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-15-3106

Cite this

@article{a05143bf653d4c2e90bf77dd9979a6e4,

title = "Arresting the inflammatory drive of chronic lymphocytic leukemia with ibrutinib",

abstract = "The clinical success of agents targeting the B-cell receptor signaling pathway in chronic lymphocytic leukemia (CLL) may also derive from disrupting the CLL microenvironment. Investigation of the immunomodulatory effects of these agents illuminates the unique immunobiology of CLL and highlights potential targets for dismantling the chronic inflammatory drive.",

author = "Pavan Bachireddy and Wu, {Catherine J.}",

note = "Publisher Copyright: {\textcopyright} 2016 American Association for Cancer Research.",

year = "2016",

month = apr,

day = "1",

doi = "10.1158/1078-0432.CCR-15-3106",

language = "English (US)",

volume = "22",

pages = "1547--1549",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "7",

}

TY - JOUR

T1 - Arresting the inflammatory drive of chronic lymphocytic leukemia with ibrutinib

AU - Bachireddy, Pavan

AU - Wu, Catherine J.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - The clinical success of agents targeting the B-cell receptor signaling pathway in chronic lymphocytic leukemia (CLL) may also derive from disrupting the CLL microenvironment. Investigation of the immunomodulatory effects of these agents illuminates the unique immunobiology of CLL and highlights potential targets for dismantling the chronic inflammatory drive.

AB - The clinical success of agents targeting the B-cell receptor signaling pathway in chronic lymphocytic leukemia (CLL) may also derive from disrupting the CLL microenvironment. Investigation of the immunomodulatory effects of these agents illuminates the unique immunobiology of CLL and highlights potential targets for dismantling the chronic inflammatory drive.

UR - http://www.scopus.com/inward/record.url?scp=84964403368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964403368&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-15-3106

DO - 10.1158/1078-0432.CCR-15-3106

M3 - Article

C2 - 26847060

AN - SCOPUS:84964403368

SN - 1078-0432

VL - 22

SP - 1547

EP - 1549

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 7

ER -

Arresting the inflammatory drive of chronic lymphocytic leukemia with ibrutinib

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this